YUNGJIN PHARM. CO., LTD
003520 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003520004
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 송파구 올림픽로35다길 13 국민연금 잠실사옥 2~3층, 송파구
- Website:
- https://eng.yungjin.co.kr/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-28 00:00 |
Regulatory Filings
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 6.1 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.2 MB | ||
| 2025-08-14 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 695.0 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 879.7 KB | ||
| 2025-08-13 00:00 |
Environmental & Social Information
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 11.1 KB | ||
| 2025-08-01 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-07-31 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 12.9 KB | ||
| 2025-07-25 00:00 |
Share Issue/Capital Change
[기재정정]신규시설투자등
|
Korean | 13.7 KB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 90.6 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 681.6 KB | ||
| 2025-05-07 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-03-28 00:00 |
AGM Information
정기주주총회결과
|
Korean | 33.7 KB | ||
| 2025-03-28 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 11.7 KB | ||
| 2025-03-20 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.2 MB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 492.1 KB |
Automate Your Workflow. Get a real-time feed of all YUNGJIN PHARM. CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for YUNGJIN PHARM. CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for YUNGJIN PHARM. CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
United States of America
ACXP
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
United States of America
ADAP
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
South Korea
179530
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
United States of America
ADCT
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
Switzerland
ADXN
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
United States of America
ADIL
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
United States of America
ACET
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
United States of America
ANL
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
United States of America
ADMA
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
United States of America
ADVM